Published in Oncogene on October 01, 1998
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Replication licensing--defining the proliferative state? Trends Cell Biol (2002) 2.91
Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts. Genes Dev (2004) 2.36
APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell (2007) 2.35
Human cyclin A is required for mitosis until mid prophase. J Cell Biol (1999) 2.31
Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase. Genes Dev (2011) 1.95
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
Variability in the control of cell division underlies sepal epidermal patterning in Arabidopsis thaliana. PLoS Biol (2010) 1.79
Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat Cell Biol (2016) 1.76
Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage. Mol Biol Cell (2007) 1.65
Switching the cell cycle. Kip-related proteins in plant cell cycle control. Plant Physiol (2005) 1.39
Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci U S A (2009) 1.37
A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system. Proc Natl Acad Sci U S A (1999) 1.28
Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res (2008) 1.18
Cyclin-dependent kinase inhibitors in maize endosperm and their potential role in endoreduplication. Plant Physiol (2005) 1.14
Preventing DNA over-replication: a Cdk perspective. Cell Div (2008) 1.01
Alternative fates of keratinocytes transduced by human papillomavirus type 18 E7 during squamous differentiation. J Virol (2002) 0.99
HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell Cycle (2011) 0.93
DNA damage triggers p21WAF1-dependent Emi1 down-regulation that maintains G2 arrest. Mol Biol Cell (2009) 0.91
p53 and regulation of bioactive sphingolipids. Adv Enzyme Regul (2010) 0.90
Replication licensing and the DNA damage checkpoint. Front Biosci (Landmark Ed) (2009) 0.90
p21(Waf1/Cip1) deficiency stimulates centriole overduplication. Cell Cycle (2006) 0.90
JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis. Exp Mol Med (2009) 0.87
Cyclin-dependent kinase inhibits reinitiation of a normal S-phase program during G2 in fission yeast. Mol Cell Biol (2009) 0.87
Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol (2001) 0.85
p21 as a transcriptional co-repressor of S-phase and mitotic control genes. PLoS One (2012) 0.85
The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol (2007) 0.82
Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1. Oncotarget (2016) 0.78
Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines. Anticancer Drugs (2014) 0.77
The effects of two polymorphisms on p21cip1 function and their association with Alzheimer's disease in a population of European descent. PLoS One (2015) 0.76
Bifurcation in Cell Cycle Dynamics Regulated by p53. PLoS One (2015) 0.75
Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells. BMC Neurosci (2017) 0.75
Connexin-43 enhances tumor suppressing activity of artesunate via gap junction-dependent as well as independent pathways in human breast cancer cells. Sci Rep (2017) 0.75
Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch (2003) 0.75
The Cytolethal Distending Toxin Subunit CdtB of Helicobacter hepaticus Promotes Senescence and Endoreplication in Xenograft Mouse Models of Hepatic and Intestinal Cell Lines. Front Cell Infect Microbiol (2017) 0.75
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore (1994) 16.38
PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Trends in medical use and abuse of opioid analgesics. JAMA (2000) 4.23
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet (1992) 3.85
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
Role of NF-kappaB in p53-mediated programmed cell death. Nature (2000) 3.62
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell (1991) 3.58
Coping with stress: multiple ways to activate p53. Oncogene (2007) 3.57
Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol (2001) 3.46
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 3.24
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol (1989) 3.00
p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene (1991) 2.76
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Regulation of p53 stability. Oncogene (1999) 2.54
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev (1996) 2.26
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol (2001) 2.09
Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell (1994) 2.06
Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol (2000) 2.02
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 1.99
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene (2000) 1.85
PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ (2009) 1.83
Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene (1990) 1.76
Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol (1997) 1.73
Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol (1998) 1.69
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mdm2 binds p73 alpha without targeting degradation. Oncogene (1999) 1.62
Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci (1999) 1.62
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene (2008) 1.60
Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev (1997) 1.59
Regulation of p53 function. Exp Cell Res (2001) 1.55
Life and death decisions by E2F-1. Cell Death Differ (2004) 1.50
Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol (1998) 1.50
Analysis of the degradation function of Mdm2. Cell Growth Differ (1999) 1.49
Cortisol, dehydroepiandrosterone sulphate, their ratio and hypertension: evidence of associations in male veterans from the Vietnam Experience Study. J Hum Hypertens (2011) 1.40
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature (1984) 1.40
New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene (2012) 1.40
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J (1992) 1.39
p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. Cell Death Differ (2007) 1.39
Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene (1996) 1.39
E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell (1999) 1.34
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog (1991) 1.33
Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene (1994) 1.32
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci U S A (1986) 1.29
Keeping an old friend under control: regulation of p53 stability. Mol Med Today (1998) 1.29
Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol (2000) 1.28
HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J (1994) 1.28
Analysis of human papillomavirus type 16 open reading frame E7 immortalizing function in rat embryo fibroblast cells. J Gen Virol (1990) 1.28
Regulation and activation of p53 and its family members. Cell Death Differ (1999) 1.27
Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol (2000) 1.27
Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene (1991) 1.26
E2F-1 induced apoptosis. Apoptosis (2001) 1.22
Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb Symp Quant Biol (2011) 1.20
ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ (2005) 1.15
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene (1998) 1.15
The ins and outs of p53. Nat Cell Biol (2000) 1.14
E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res (1996) 1.14
Human papillomavirus detection by hybrid capture and its possible clinical use. J Clin Pathol (1994) 1.11
Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis (2010) 1.10
Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma. EMBO J (1984) 1.07
Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer (1992) 1.06
Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol (1997) 1.06
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum (1998) 1.05
Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. Cancer Res (1999) 1.05
Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women. J Hum Hypertens (2012) 1.04
Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene (1993) 1.03
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis (2010) 1.02
DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene (2006) 1.02
Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene (1995) 1.02
Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene (1994) 0.99
Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene (1994) 0.99
Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol (1994) 0.98
Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology (1996) 0.96
New HPV E6 binding proteins: dangerous liaisons? Trends Microbiol (1998) 0.96
Synthesis and characterization of dimensionally ordered semiconductor nanowires within mesoporous silica. J Am Chem Soc (2001) 0.93
Reversal of p53-induced cell-cycle arrest. Mol Carcinog (1999) 0.93
Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Ther (2008) 0.93
Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol (1991) 0.90
Developmental differences in reactions to the physically disabled. Hum Dev (1981) 0.89